A review on the current status of homeopathy in the clinical management of cancer
Curr Drug Targets. 2022 Aug 16. doi: 10.2174/1389450123666220816151547. Online ahead of print.ABSTRACTHomeopathy is a widely practiced alternate system of medicine around the world that employs small doses of various medicines to promote auto-regulation and self-healing. It is among the most commonly used alternative approaches in cancer as well as other diseases, among other alternate therapeutic systems. It is widely used as palliative and as supportive therapy in cancer patients. Few cases have been reported on patients using homeopathy after surgery, radiotherapy, and chemotherapy, generally for overcoming side effects...
Source: Current Drug Targets - August 17, 2022 Category: Drugs & Pharmacology Authors: Ajay Tangelloju Rudra Chakravarti Rajveer Singh Bireswar Bhattacharya Arijit Ghosh Sujit Kumar Bhutia Velayutham Ravichandiran Dipanjan Ghosh Source Type: research

Oncostatin M: Risks and benefits of a Novel Therapeutic Target for Atherosclerosis
CONCLUSION: While OSM may be of therapeutic value in atherosclerosis, drug development should also focus on de-risking the herein identified major safety concerns: tissue remodeling, angiogenesis, bleeding, anemia, and NMDA- and glutamate-induced neurotoxicity. Close monitoring and/or exclusion of patients with various comorbidities may be required for optimal therapeutic benefit.PMID:35959619 | DOI:10.2174/1389450123666220811101032 (Source: Current Drug Targets)
Source: Current Drug Targets - August 12, 2022 Category: Drugs & Pharmacology Authors: Tanja Rouhani Rankouhi Dani ëlle van Keulen Dennie Tempel Jennifer Venhorst Source Type: research

Oncostatin M: Risks and benefits of a Novel Therapeutic Target for Atherosclerosis
CONCLUSION: While OSM may be of therapeutic value in atherosclerosis, drug development should also focus on de-risking the herein identified major safety concerns: tissue remodeling, angiogenesis, bleeding, anemia, and NMDA- and glutamate-induced neurotoxicity. Close monitoring and/or exclusion of patients with various comorbidities may be required for optimal therapeutic benefit.PMID:35959619 | DOI:10.2174/1389450123666220811101032 (Source: Current Drug Targets)
Source: Current Drug Targets - August 12, 2022 Category: Drugs & Pharmacology Authors: Tanja Rouhani Rankouhi Dani ëlle van Keulen Dennie Tempel Jennifer Venhorst Source Type: research

Oncostatin M: Risks and benefits of a Novel Therapeutic Target for Atherosclerosis
CONCLUSION: While OSM may be of therapeutic value in atherosclerosis, drug development should also focus on de-risking the herein identified major safety concerns: tissue remodeling, angiogenesis, bleeding, anemia, and NMDA- and glutamate-induced neurotoxicity. Close monitoring and/or exclusion of patients with various comorbidities may be required for optimal therapeutic benefit.PMID:35959619 | DOI:10.2174/1389450123666220811101032 (Source: Current Drug Targets)
Source: Current Drug Targets - August 12, 2022 Category: Drugs & Pharmacology Authors: Tanja Rouhani Rankouhi Dani ëlle van Keulen Dennie Tempel Jennifer Venhorst Source Type: research

Oncostatin M: Risks and benefits of a Novel Therapeutic Target for Atherosclerosis
CONCLUSION: While OSM may be of therapeutic value in atherosclerosis, drug development should also focus on de-risking the herein identified major safety concerns: tissue remodeling, angiogenesis, bleeding, anemia, and NMDA- and glutamate-induced neurotoxicity. Close monitoring and/or exclusion of patients with various comorbidities may be required for optimal therapeutic benefit.PMID:35959619 | DOI:10.2174/1389450123666220811101032 (Source: Current Drug Targets)
Source: Current Drug Targets - August 12, 2022 Category: Drugs & Pharmacology Authors: Tanja Rouhani Rankouhi Dani ëlle van Keulen Dennie Tempel Jennifer Venhorst Source Type: research

Oncostatin M: Risks and benefits of a Novel Therapeutic Target for Atherosclerosis
CONCLUSION: While OSM may be of therapeutic value in atherosclerosis, drug development should also focus on de-risking the herein identified major safety concerns: tissue remodeling, angiogenesis, bleeding, anemia, and NMDA- and glutamate-induced neurotoxicity. Close monitoring and/or exclusion of patients with various comorbidities may be required for optimal therapeutic benefit.PMID:35959619 | DOI:10.2174/1389450123666220811101032 (Source: Current Drug Targets)
Source: Current Drug Targets - August 12, 2022 Category: Drugs & Pharmacology Authors: Tanja Rouhani Rankouhi Dani ëlle van Keulen Dennie Tempel Jennifer Venhorst Source Type: research

Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia
Curr Drug Targets. 2022 Aug 10. doi: 10.2174/1389450123666220810102406. Online ahead of print.ABSTRACTCovid-19 may be associated with various neurological disorders, including dysautonomia, a dysfunction of the autonomic nervous system (ANS). In Covid-19, hypoxia, immuno-inflammatory abnormality, and deregulation of the renin-angiotensin system (RAS) may increase sympathetic discharge with dysautonomia development. Direct SARS-CoV-2 cytopathic effects and associated inflammatory reaction may lead to neuroinflammation, affecting different parts of the central nervous system (CNS), including the autonomic center in the hypot...
Source: Current Drug Targets - August 11, 2022 Category: Drugs & Pharmacology Authors: Hayder M Al-Kuraishy Ali I Al-Gareeb Athanasios Alexiou Gaber El-Saber Batiha Source Type: research

Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia
Curr Drug Targets. 2022 Aug 10. doi: 10.2174/1389450123666220810102406. Online ahead of print.ABSTRACTCovid-19 may be associated with various neurological disorders, including dysautonomia, a dysfunction of the autonomic nervous system (ANS). In Covid-19, hypoxia, immuno-inflammatory abnormality, and deregulation of the renin-angiotensin system (RAS) may increase sympathetic discharge with dysautonomia development. Direct SARS-CoV-2 cytopathic effects and associated inflammatory reaction may lead to neuroinflammation, affecting different parts of the central nervous system (CNS), including the autonomic center in the hypot...
Source: Current Drug Targets - August 11, 2022 Category: Drugs & Pharmacology Authors: Hayder M Al-Kuraishy Ali I Al-Gareeb Athanasios Alexiou Gaber El-Saber Batiha Source Type: research

Redox interactions in chemo/radiation therapy-induced lung toxicity; mechanisms and therapy perspectives
Curr Drug Targets. 2022 Jul 5. doi: 10.2174/1389450123666220705123315. Online ahead of print.ABSTRACTLung toxicity is a key limiting factor for the therapy of cancer, especially lung, breast, and esophageal malignancies. Radiotherapy for chest and breast malignancies can cause lung injury. However, systemic cancer therapy with chemotherapy also may induce lung pneumonitis and fibrosis. Radiotherapy produces reactive oxygen species (ROS) directly via interacting with water molecules within cells. However, radiation and other therapy modalities may induce the endogenous generation of ROS and nitric oxide (NO) by immune cells...
Source: Current Drug Targets - July 6, 2022 Category: Drugs & Pharmacology Authors: Xixi Lai Masoud Najafi Source Type: research

Redox interactions in chemo/radiation therapy-induced lung toxicity; mechanisms and therapy perspectives
Curr Drug Targets. 2022 Jul 5. doi: 10.2174/1389450123666220705123315. Online ahead of print.ABSTRACTLung toxicity is a key limiting factor for the therapy of cancer, especially lung, breast, and esophageal malignancies. Radiotherapy for chest and breast malignancies can cause lung injury. However, systemic cancer therapy with chemotherapy also may induce lung pneumonitis and fibrosis. Radiotherapy produces reactive oxygen species (ROS) directly via interacting with water molecules within cells. However, radiation and other therapy modalities may induce the endogenous generation of ROS and nitric oxide (NO) by immune cells...
Source: Current Drug Targets - July 6, 2022 Category: Drugs & Pharmacology Authors: Xixi Lai Masoud Najafi Source Type: research

Redox interactions in chemo/radiation therapy-induced lung toxicity; mechanisms and therapy perspectives
Curr Drug Targets. 2022 Jul 5. doi: 10.2174/1389450123666220705123315. Online ahead of print.ABSTRACTLung toxicity is a key limiting factor for the therapy of cancer, especially lung, breast, and esophageal malignancies. Radiotherapy for chest and breast malignancies can cause lung injury. However, systemic cancer therapy with chemotherapy also may induce lung pneumonitis and fibrosis. Radiotherapy produces reactive oxygen species (ROS) directly via interacting with water molecules within cells. However, radiation and other therapy modalities may induce the endogenous generation of ROS and nitric oxide (NO) by immune cells...
Source: Current Drug Targets - July 6, 2022 Category: Drugs & Pharmacology Authors: Xixi Lai Masoud Najafi Source Type: research

Redox interactions in chemo/radiation therapy-induced lung toxicity; mechanisms and therapy perspectives
Curr Drug Targets. 2022 Jul 5. doi: 10.2174/1389450123666220705123315. Online ahead of print.ABSTRACTLung toxicity is a key limiting factor for the therapy of cancer, especially lung, breast, and esophageal malignancies. Radiotherapy for chest and breast malignancies can cause lung injury. However, systemic cancer therapy with chemotherapy also may induce lung pneumonitis and fibrosis. Radiotherapy produces reactive oxygen species (ROS) directly via interacting with water molecules within cells. However, radiation and other therapy modalities may induce the endogenous generation of ROS and nitric oxide (NO) by immune cells...
Source: Current Drug Targets - July 6, 2022 Category: Drugs & Pharmacology Authors: Xixi Lai Masoud Najafi Source Type: research

Redox interactions in chemo/radiation therapy-induced lung toxicity; mechanisms and therapy perspectives
Curr Drug Targets. 2022 Jul 5. doi: 10.2174/1389450123666220705123315. Online ahead of print.ABSTRACTLung toxicity is a key limiting factor for the therapy of cancer, especially lung, breast, and esophageal malignancies. Radiotherapy for chest and breast malignancies can cause lung injury. However, systemic cancer therapy with chemotherapy also may induce lung pneumonitis and fibrosis. Radiotherapy produces reactive oxygen species (ROS) directly via interacting with water molecules within cells. However, radiation and other therapy modalities may induce the endogenous generation of ROS and nitric oxide (NO) by immune cells...
Source: Current Drug Targets - July 6, 2022 Category: Drugs & Pharmacology Authors: Xixi Lai Masoud Najafi Source Type: research

Redox interactions in chemo/radiation therapy-induced lung toxicity; mechanisms and therapy perspectives
Curr Drug Targets. 2022 Jul 5. doi: 10.2174/1389450123666220705123315. Online ahead of print.ABSTRACTLung toxicity is a key limiting factor for the therapy of cancer, especially lung, breast, and esophageal malignancies. Radiotherapy for chest and breast malignancies can cause lung injury. However, systemic cancer therapy with chemotherapy also may induce lung pneumonitis and fibrosis. Radiotherapy produces reactive oxygen species (ROS) directly via interacting with water molecules within cells. However, radiation and other therapy modalities may induce the endogenous generation of ROS and nitric oxide (NO) by immune cells...
Source: Current Drug Targets - July 6, 2022 Category: Drugs & Pharmacology Authors: Xixi Lai Masoud Najafi Source Type: research

Redox interactions in chemo/radiation therapy-induced lung toxicity; mechanisms and therapy perspectives
Curr Drug Targets. 2022 Jul 5. doi: 10.2174/1389450123666220705123315. Online ahead of print.ABSTRACTLung toxicity is a key limiting factor for the therapy of cancer, especially lung, breast, and esophageal malignancies. Radiotherapy for chest and breast malignancies can cause lung injury. However, systemic cancer therapy with chemotherapy also may induce lung pneumonitis and fibrosis. Radiotherapy produces reactive oxygen species (ROS) directly via interacting with water molecules within cells. However, radiation and other therapy modalities may induce the endogenous generation of ROS and nitric oxide (NO) by immune cells...
Source: Current Drug Targets - July 6, 2022 Category: Drugs & Pharmacology Authors: Xixi Lai Masoud Najafi Source Type: research